(PO24-39-22) Probiotics, a Novel and Efficient Adjuvant Therapy in Improving Glycemic Status: An Umbrella Meta-Analysis

The ePoster content is available to NUTRITION 2022 LIVE ONLINE attendees who are logged in.<br><br>If you are registered, log in and then come back here to use this button.

Presenting Author(s)

Meysam Zarezadeh, PhD Candidate
– Ph.D. Candidate, Tabriz University of Medical Sciences, School of Nutrition and Food Science, Tabriz, Azarbayjan-e Sharqi, Iran

Co-Author(s)

PD

Parvin Dehghan
– Tabriz University of Medical Sciences
AF

Amir Hossein Faghfouri
– Tabriz University of Medical Sciences
VM

Vali Musazadeh
– Tabriz University of Medical Sciences

Disclosure(s):

Meysam Zarezadeh, PhD Candidate: No relevant financial relationship(s) with ineligible companies to disclose.

Objectives: Probiotics exert several promoting effects on the glycemic status, however, the results of meta-analyses are inconsistent. As a result, this paper conducted an umbrella meta-analysis, across existing systematic reviews and meta-analyses of clinical trials to determine the definite effects of supplementation with probiotics on glycemic indices

Methods: Meta-analysis studies of randomized clinical trials examining the impacts of probiotics supplementation on glycemic indices were qualified in the current umbrella meta-analysis. A comprehensive systematic search of PubMed/Medline, Scopus, EMBASE, and Web of Science was carried out till August 2021. Effect sizes (ES) and corresponding confidence intervals (CIs ) were employed to obtain the overall effect sizes. I² statistics and Cochrane’s Q-test was used to detect the heterogeneity. The random-effects model was employed to conduct meta-analysis.

Results: 48 articles out of 693 in the literature search qualified for inclusion in the umbrella meta-analysis. Pooled effects of probiotics on fasting plasma glucose (FPG), hemoglobin A1C (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), and insulin levels were reported in 45, 21, 35, and 33 articles, respectively. The analysis indicated a significant decrease of FPG (ES= -0.51 mg/dL; 95% CI: -0.63, -0.38, p< 0.001), HbA1c (ES = -0.32 mg/dL; 95% CI: -0.44, -0.20, p< 0.001), HOMA-IR (ES= -0.56; 95% CI: -0.66, -0.47, p< 0.001), and insulin levels (ES= -1.09 IU/mL; 95% CI: -1.37, -0.81, p= 0.006) by probiotics supplementation .

Conclusions: Probiotics have amending effects on FPG, HbA1c, HOMA-IR, and insulin levels. A < 8-week period of probiotic supplementation in the moderate dosages (10⁸ or 10⁹ CFU) is an efficacious approach in improving glycemic parameters. Overall, probiotics could be recommended as an adjuvant anti-hyperglycemic agent.

Funding Sources: None